Citation & Authors
Diabetes Res Clin Pract. 2025;226:112328.
ABSTRACT · RESEARCH SUMMARY
Research summary
This Taiwanese National Health Insurance study matched 20,655 pairs of SGLT2/DPP-4 inhibitor users and 10,445 pairs of SGLT2/GLP-1 users, all receiving insulin. SGLT2 inhibitors were associated with fewer major microvascular complications, with aHRs of 0.37 and 0.57 in the two comparisons. Major cardiovascular events and death were also less frequent than with DPP-4 inhibitors.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
